Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.22.32 (bromelain)
 1,025 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Radioimmunoassays (RIA) have confirmed previous studies that trimethylammonium (TMA) or its derivatives constitute part of the determinant recognized by naturally-occurring antibodies (NOA) with the ability to interact with bromelain-treated mouse erythrocytes (BrMRBC). Further studies on this determinant revealed its presence on erythrocytes from several species in addition to mice. In most cases (except in chickens) the determinant was cryptic and could be exposed only after proteolytic treatment of the erythrocytes. The determinant was also found on certain murine lymphoma cells. We also found that bromelain was not the only enzyme that could be used to expose the determinant. Papain, but not trypsin, was able to unmask the determinant on mouse erythrocytes. Rabbit antibodies directed against the idiotypes of four different monoclonal BrMRBC-binding NOA were prepared. Direct RIA assays and inhibition assays showed that the different monoclonal BrMRBC-binding NOA shared a common idiotype specific to such antibodies. The common idiotype was detected in the serum from several mouse strains and in wild mice.
 ...
PMID:Further studies on the determinant recognized by naturally-occurring murine autoantibodies reacting with bromelain-treated erythrocytes. 245 52

In order to study the heterogeneity of the anti-erythrocyte auto-antibody response in NZB mice, we have developed hybridomas producing monoclonal auto-antibodies with anti-erythrocyte activity. These monoclonals were prepared by fusion of NZB splenocytes with the P3 X 63.Ag8 myeloma and were screened for activity by indirect immunofluorescence using flow cytometry. We have produced a variety of monoclonal anti-red cell auto-antibodies that have differing antigenic reactivities and immunoglobulin isotypes. Eleven monoclonal antibodies extensively studied thus far react with intact mouse erythrocytes, whereas only two of the eleven also cross react with sheep erythrocytes and bromelain treated mouse erythrocytes. These results suggest that the fusion pattern may represent the range of anti-red cell auto-antibodies found in the intact NZB mouse, with the exception of monoclonal auto-antibodies against cryptic red cell auto-antigens, which were not demonstrated in this initial fusion study.
 ...
PMID:Monoclonal anti-erythrocyte auto-antibodies from unimmunized NZB mice. 692 51

Spleen, lymph node, and peripheral blood lymphocytes from healthy guinea pigs (gp) were examined for their ability to produce polyreactive autoantibodies to a battery of self-antigens and to cryptic determinants (phosphatidylcholine) on bromelain-treated mouse red blood cells (Br-MRBC). The mouse monoclonal antibody (Mab) 8BE6 anti-gp pan-T (CD5) marker was used for identification of CD5+ B1 cells by the plaque-forming assay (PFC), immunofluorescence, complement-mediated cytotoxicity, and immunocytochemistry. The detection of CD5+ cells by the 8BE6 Mab depended on the method used. They were better demonstrated by cytolysis and immunocytochemistry than by FACS analysis. By the latter method, the level of the CD5+ B cell subpopulation was associated neither with the age of the gp nor with the organ examined. Similarly wide ranges of PFC were detected in untreated or LPS-treated animals regardless of age and organ. The vast majority of the LPS-stimulated IgM antibody-secreting B lymphocytes reacting with the Br-MRBC, and those producing natural autoantibodies, did not bind the 8BE6 Mab.
 ...
PMID:CD5+ and CD5- B1-like lymphocytes in healthy guinea pig. 934 96